Tyrosine kinase 2 (TYK2) is a member of the Janus kinase (JAK) family of nonreceptor tyrosine kinases, which are essential for proper signaling in immune responses and development. Here we present a 2.0-Å-resolution crystal structure of a receptorbinding fragment of human TYK2, encompassing the FERM and SH2 domains, in complex with a so-called 'box2'-containing intracellular peptide motif from the interferon-a receptor chain 1 (IFNAR1). The TYK2-IFNAR1 interface reveals an unexpected receptor-binding mode that mimics a SH2 domain-phosphopeptide interaction, with a glutamate replacing the canonical phosphotyrosine residue. This structure provides the first view, to our knowledge, of a JAK in complex with its cognate receptor and defines the molecular logic through which JAKs have evolved to interact with divergent receptor sequences.
JAKs are essential mediators of cytokine and interferon signaling through type I and type II cytokine receptors, and they drive processes as diverse as adaptive immune functions, hematopoiesis, metabolism and cellular growth 1 . The four JAK family members (JAK1, JAK2, JAK3 and TYK2) are large multidomain kinases that lack a transmembrane component and instead constitutively associate with membrane-proximal peptide motifs found on the intracellular sides of cytokine receptors 2 . JAKs share a common domain structure, containing N-terminal FERM and SH2-like domains that mediate receptor interactions and C-terminal pseudokinase and kinase domains that regulate kinase activity. Ligand-induced dimerization of two JAK-bound receptors initiates kinase activation and a signaling cascade that ultimately results in dimerization and activation of the STAT transcription factors and subsequent transcription of cytokineresponsive genes 1 . In accordance with their critical importance in immune and growth-factor pathways, JAK mutations can be found in human ailments such as immunodeficiency syndromes and myeloproliferative diseases 3 , and therapeutic JAK inhibition has been explored for immune disorders and cancer 4 .
Given the noncovalent association of JAKs with cytokine receptors, the receptor-JAK interaction is a critical link between extracellular ligand-mediated receptor dimerization and activation of signaling. Receptor intracellular sequences are key for both JAK tethering and regulation of kinase activity 2 , yet molecular details of the linkage mechanism remain enigmatic. Important clues can be gathered from in vitro studies showing that both the FERM and SH2-like domains of JAK have key structural roles in receptor binding [5] [6] [7] [8] [9] and mediate specific association with two receptor peptide motifs termed 'box1' and box2 (ref. 10) . Box1 is a membrane-proximal proline-rich segment, and it is followed by the hydrophobic box2 motif 10 to 40 residues downstream. Many studies implicate receptor box1 and box2 sequences in JAK association and kinase activation [10] [11] [12] [13] [14] [15] [16] [17] , and regions outside box1 and box2 are also important for JAK interaction 11, 13, 15, 18 . Unfortunately, the poor conservation of receptor intracellular sequences and a lack of structural information make it impossible to decipher the receptor 'code' that enables interaction of individual JAKs with specific receptors. In other words, how four JAK family members interact with and are activated by more than 30 different cytokine receptors with exquisite affinity and specificity remains a fundamental question in the field.
The type 1 interferons are a family of 16 distinct cytokines involved in the triggering of innate immune responses against viral and bacterial infection 19, 20 . Members of the interferon (IFN)-α and IFN-β family, in addition to being critically important in the pathogen response, act as important regulators of tumor immunity 21 and play a substantial role in the pathophysiology of autoimmune diseases 22 . All type 1 interferons initiate signaling through dimerization of the IFNAR1 and IFNAR2 receptors, whose intracellular domains are associated with TYK2 and JAK1, respectively. The connection between TYK2 and IFNAR1 was one of the first JAK-receptor relationships to be genetically and biochemically characterized [23] [24] [25] , and it is unique in that TYK2 has been shown to be required for IFNAR1 cellular trafficking in vivo 25, 26 . Additionally, a peptide sequence within the intracellular domain of IFNAR1 (residues 465 to 511) is necessary for the interaction with TYK2 as well as for TYK2 signaling 13 . Within this IFNAR1 fragment, the box2 motif, as well as a number of residues along a 20-residue section, is necessary for TYK2 binding, thus suggesting that multiple amino acid contacts along the length of this peptide interact with TYK2.
There are currently no crystal structures available, to our knowledge, for any JAK bound to a cytokine receptor, and this has severely limited the interpretation of the receptor-interaction sequences as well as the understanding of the mechanisms of JAK activation. To address these fundamental questions, we set out to determine the structure of the FERM and SH2-like domains from human TYK2 in complex with a peptide from IFNAR1 that is necessary and a r t i c l e s sufficient for signaling through the type 1 interferon-receptor system. This structure provides a model for the highly unique and conserved mechanism by which JAKs interact with their cognate receptors and suggests an unexpected evolutionary path for JAK-associated receptor signaling systems.
RESULTS
The structure of the TYK2 FERM-SH2 receptor-binding domain JAKs in general have proven to be difficult crystallography targets, owing to their poor solubility when expressed and purified alone 27 . Given their constitutive association with cytokine receptors in vivo, we reasoned that the JAK FERM and SH2-like receptor-binding domains (FERM-SH2) might require a receptor peptide for in vitro stability. Taking advantage of biochemical studies delineating the region of the IFNAR1 intracellular domain required for TYK2 binding 13 , we cloned and expressed the human TYK2 FERM-SH2 (residues 23-583) as a fusion protein connected to this IFNAR1 fragment (residues 465-512) ( Fig. 1a) . This construct provided high levels of stable, monodisperse protein, whereas the TYK2 fragment by itself was prone to aggregation when assessed by size-exclusion chromatography (SEC) ( Supplementary Fig. 1 ). To ensure that the IFNAR1 peptide was constitutively associated with the TYK2 FERM-SH2, we cleaved a construct containing a site-specific protease-cleavage site within the linker between TYK2 and the IFNAR1 peptide and analyzed the TYK2-IFNAR1 complex by SEC ( Supplementary  Fig. 1 ). We then validated peptide association by SDS-PAGE and MS (Supplementary Fig. 1) . The TYK2 FERM-SH2 and IFNAR1 peptide comigrated on the size-exclusion column, thus confirming that the IFNAR1 peptide was bound to TYK2 in solution. Using an analogous TYK2-IFNAR1 construct containing a noncleavable linker, we crystallized the complex and obtained a native data set at 2.0-Å resolution ( Table 1 and Supplementary Fig. 2 ). We obtained phases by gold and platinum derivatization of native crystals and solved the structure by using the single-wavelength anomalous dispersion (SAD) method (Online Methods).
The data provided well-defined electron density for generation of a model of the FERM and SH2 domains as well as 19 residues from the IFNAR1 peptide ( Table 1 and Fig. 1b,c) and reveal that the FERM and SH2 domains form a contiguous, Y-shaped receptorbinding module that interacts with the receptor peptide via a composite interface formed by the FERM F2 and SH2 domains. Analysis of the crystal packing demonstrates that the peptide is not part of a crystal contact, thus ruling out lattice-mediated stabilization of peptide in the structure (Supplementary Fig. 2 ).
The TYK2 FERM domain (residues 26-430) displays the trilobed cloverleaf structure found in FERM domains from the ezrin, radixin and moesin family [28] [29] [30] as well as focal adhesion kinase 31 ( Fig. 1b and Supplementary Fig. 3 ). Alignment of the TYK2 FERM with other JAK family members indicates that this overall domain structure is conserved among the four paralogs ( Supplementary Fig. 3 ). The first subdomain (F1, residues 26-107) consists of a ubiquitin-like domain and a 37-residue insertion (L1) that interacts with the C terminus of the SH2 domain as well as the IFNAR1 peptide ( Supplementary  Fig. 4 ). The second subdomain (F2, residues 145-271) is entirely helical and has homology to an acyl-CoA-binding protein fold. An intriguing feature of this subdomain is a basic patch on the α2′, α2″ and α3 helices ( Fig. 1d,e ). These three helices contain 15 surfaceexposed basic residues, with nine of these positions conserved in at least three of the four human JAK family members ( Supplementary  Fig. 3 ). Given the positive surface charge of the F2 subdomain, we speculate that in vivo this region may lie in proximity to the phosphatidyl lipid head groups of the plasma membrane. The third subdomain (F3, residues 272-430) retains the topology of a pleckstrinhomology (PH) domain and contains two large disordered loops between the β1 and β2 (residues 296-308) and β3 and β4 (residues 330-370) strands.
The SH2 domain of TYK2 (residues 452-551) interacts intimately with the FERM domain and is held in place next to the F1 lobe of the FERM by L1 as well as two SH2-flanking linkers (L2 and L3, residues 431-451 and 552-566, respectively) ( Supplementary Fig. 4 ). The core of the TYK2 SH2 domain adopts a characteristic SH2 fold 32 Fig. 4 ).
Canonical features of SH2 βE, βF and BG loops are retained in the TYK2 SH2, with the βE and βF strands forming a wide loop (the EF loop) and the BG loop organized into a two-strand β sheet (βG1 and βG2) that is a key part of the receptor-binding interface.
As with the FERM domain, SH2 and linker-sequence homology between JAK family members indicates that the overall fold is conserved ( Supplementary Fig. 3) ; therefore, this structure provides an initial template for this critical scaffolding region within the JAK family.
IFNAR1 resembles a SH2-binding phosphopeptide
The IFNAR1 peptide interaction interface is approximately linear and buries ~1,246 Å 2 of TYK2 surface area, as might be anticipated for a constitutive interaction interface. The IFNAR1 peptide can be structurally organized into three segments, each anchored by several residues that make important contacts with TYK2. Segment 1 is anchored by a key dileucine motif (Leu491 and Leu492) that interacts with a hydrophobic groove generated by the L1 and α1 helix of the F2 domain ( Fig. 2a ). Leu491 interacts with TYK2 residues Leu144, Pro146 and Phe149, whereas Leu492 points ~120° away from the Leu491 side chain and inserts into a pocket lined by Gly140, Gln142 and Asp145. C-terminal to Leu492, IFNAR1 loses contact with TYK2 for two residues and regains it with a hydrogen bond between the backbone carbonyl of Ser495 and TYK2 Thr477 (Fig. 2b) . This second segment of the peptide is secured by polar interactions between Glu497 and TYK2 Ser476 and Thr477, and by a water-mediated hydrogen bond with TYK2 Arg482. Other important contacts with segment 2 include van der Waals contacts between Ile499 and TYK2 Pro506 as well as a salt bridge between Glu500 and TYK2 Arg503. The third segment of the IFNAR1 peptide includes the receptor's canonical box2 motif, which is a weakly conserved stretch of four hydrophobic amino acids npg a r t i c l e s generally followed by one to two negatively charged residues 10 . The box2 segment forms a three-residue β-sheet with the βG1 strand of the SH2 domain, with side chains of residues Cys502 and Ile504 buried in a hydrophobic groove formed by the βG1 strand and EF loop ( Fig. 2c) . Overall, IFNAR1 uses degenerate nonpolar interactions at both ends combined with specific polar contacts in segment 2 to bind TYK2 with high affinity and fidelity.
Comparison of the TYK2 SH2 with known SH2-domain structures reveals the closest structural homologs to be the N-terminal SH2 domains of the SHP family phosphatases 33, 34 ( Supplementary  Fig. 4) . The tandem SH2 domains of SHP1 and SHP2 bind phosphorylated tyrosine-containing peptides in target receptors and are classical SH2 folds that use a conserved arginine residue in the βB strand to coordinate the phosphate group. Unlike a classical SH2, the TYK2 SH2 domain does not appear to be competent for phosphotyrosine binding, owing to the presence of a histidine (His474) residue at this essential arginine position ( Fig. 3a) . Yet, unexpectedly, comparison of the TYK2 SH2 with the SHP2 N-terminal SH2 domain reveals that the positioning of the IFNAR1 peptide resembles that of the SHP2-bound IRS-1 phosphopeptide, with the TYK2 SH2 phosphotyrosine-binding site instead playing a pivotal part in IFNAR1 recognition by binding a glutamate residue ( Fig. 3a,b and Supplementary Fig. 4 ). The IFNAR1 Glu497 carboxylate forms two hydrogen bonds with TYK2 SH2 residues Ser476 and Thr477 (Fig. 3a) , thus mimicking the interaction of phosphotyrosine with SHP2 residues Ser34 and Lys35 (Fig. 3b) . Unlike a phosphate group, the Glu497 carboxylate is fully coordinated by residues Ser476 and Thr477 and therefore does not require interaction with His474. This surprising result illuminates studies in which the conserved JAK1 and JAK2 SH2 arginine was shown to be dispensable for receptor binding 2 .
SH2-interacting peptides often contain hydrophobic residues C terminal to the phosphotyrosine that function as specificity elements for peptide recognition 35 . The hydrophobic box2 region of IFNAR1 (segment 3) begins five residues C-terminal to Glu497 at Cys502. The side chains of Cys502 and Ile504 are buried in the hydrophobic βG1-EF groove and, along with Phe503, form a short β-sheet with the βG1 strand ( Fig. 3c) . Comparison to the IRS-1 peptide bound to SHP2 shows that the isoleuceine (at position 3) and phenylalanine (position 5) residues are similarly buried in a hydrophobic groove, and the glutamate (position 4) residue makes a backbone hydrogen bond with the BG loop ( Fig. 3d) . Therefore, the interaction of the IFNAR1 box2 with the TYK2 SH2 appears to mimic specificitydetermining contacts found in classical SH2-phosphopeptide interactions. Our structure suggests that Cys502 and Ile504 rely on main chain hydrogen-bonding and van der Waals contacts for binding energy, thus implying that the SH2 groove in TYK2 can bind a range of sequences that contain aliphatic residues in the first and third positions. This finding now provides a structural rationale for the sequence diversity found in JAK-interacting box2 sequences.
IFNAR1 interface residues are key for TYK2 interaction
We tested, on the basis of our structural analysis, the importance of the IFNAR1 contact residues N terminal to the box2 for stabilization of the TYK2 FERM-SH2 in vitro by engineering a number of site-directed IFNAR1 alanine mutations in the TYK2-IFNAR1 Figure 3 The TYK2-IFNAR1 complex resembles a SH2-phosphopeptide interaction. Comparison of the TYK2 SH2 interaction with IFNAR1 side by side with the SHP2-SH2 domain bound to a phosphotyrosine (pTyr) peptide from IRS-1 (PDB 1AYB) 34 npg a r t i c l e s single-chain fusion construct and testing protein behavior in a thermal stability assay. Apparent melting temperature (T m ) values were reduced by more than 5 °C for the L491A L492A, E497A and E496A E497A and E500A mutants when compared to wild type ( Fig. 4a  and Supplementary Fig. 5) , with the solvent-facing E496A mutant having a more limited effect (~1 °C) on TYK2 stability. These data indicate that the interactions mediated by IFNAR1 L491A L492A, E497A or E500A are important for the stability of the TYK2 FERM-SH2 domain. We also investigated the importance of IFNAR1 Glu497 in formation of the TYK2-IFNAR1 complex by performing reciprocal pulldown experiments from insect cells expressing TYK2 FERM-SH2 and IFNAR1 variants. Pulldown of either histidine-tagged TYK2 FERM-SH2 or glutathione S-transferase (GST)-linked IFNAR1 peptide shows that mutation of Glu497 to alanine disrupts the interaction of IFNAR1 with TYK2, whereas mutation of neighboring Glu496 has little effect (Fig. 4b,c and Supplementary Fig. 6 ). Therefore IFNAR1 Glu497, which mimics the phosphotyrosine found in classical peptide-SH2 interactions, is required for IFNAR1 binding to TYK2.
Comparison of IFNAR1 orthologs from multiple species shows high conservation of these interface residues (Fig. 5a) , whereas alignment of JAK-interacting sequences on the basis of predicted box2 sequences (Fig. 5b) shows a preference for acidic residues in the −5 and −2 positions in relation to the first box2 residue. Interestingly, the dileucine motif is not highly conserved among JAK-interacting receptors. On the other side of the interaction, sequence conservation analysis of >140 diverse JAK family homologs ( Supplementary Table 1 ) mapped onto the TYK2 FERM-SH2 structure highlights an elevated level of conservation in residues along the receptor-binding interface (Fig. 5c) . Overall, there is a high level of conservation on both sides of the TYK2-IFNAR1 interface. We therefore predict that other JAKs will follow this SH2-mediated interaction blueprint to bind their cognate receptors (discussed below).
DISCUSSION
It has long been appreciated that the role of many SH2 domains is to reversibly target a SH2-containing protein to a specific phosphorylated receptor 35 . Unique cases include the SH2 domain of SAP, which binds unphosphorylated, tyrosine-containing SLAM receptor peptides 36 , and the Saccharomyces cervisiae SPT6 SH2 domain, which binds phosphoserine 37 . To our knowledge, the interaction of a SH2 domain with a glutamate residue as seen in the TYK2-IFNAR1 complex has not been previously described. Importantly, a requirement for the Glu-Glu motif at positions 496 and 497 was demonstrated for the IFNAR1 interaction with TYK2 (ref. 13) , and alanine scanning of the erythropoietin receptor (EPO-R) has established a need for an aspartate and several surrounding residues in assays for JAK2 function 11 . It therefore seems plausible that what began as a conditional, SH2-mediated interaction between a primordial JAK-receptor pair has evolved into a constitutive interaction in its current form. This evolution required, beyond the tyrosine-to-glutamate substitution, the expansion of the box2 interaction site formed by the SH2 EF and BG loops, which are characteristic gatekeepers of peptide specificity 35, 38 . Indeed, expansion of contacts within this secondary site is one mechanism by which the SAP SH2 domain has evolved to bind an unphosphorylated tyrosine-containing peptide 36 . Given the role of a subset of FERM domains in recognition of peptide 'tails' from cell-surface receptors such as integrins 39 , a possible scenario could have involved addition of a peptide-binding FERM domain to a primitive SH2-containing JAK kinase, followed by evolution of both domains to form a tight, constitutive interaction with receptor.
Recent work characterizing the evolution of phosphorylation sites to and from fixed-charge acidic residues has suggested that these amino acid positions often regulate allosteric changes that affect protein function 40 . Our structure suggests that evolution of protein-protein interactions from conditional to constitutive is also a possibility. Like TYK2, two other uncharacterized SH2 domaincontaining proteins (RIN2 and SH2D5) in the human proteome contain arginine substitutions at the key phosphate-coordination position 41 . It is also noteworthy that, whereas TYK2 homologs have a histidine, glutamine or arginine in this position, other JAK family members retain an arginine, a residue that probably would also permit interaction with an acidic residue. Indeed, the presence of glutamate or aspartate residues in a number of JAK1-, JAK2-and JAK3associated receptors suggests that this is the case. In addition, some uncharacterized SH2 domains in the human proteome may have functions other than binding phosphotyrosine.
A molecular understanding of JAK-receptor interactions is key to elucidation of the mechanisms of JAK activation, yet insight into these interactions has been hampered by the poor sequence conservation and ambiguity in binding requirements between different JAK-receptor systems. Study of the JAK1-gp130 and JAK2-EPO-R systems has established a general requirement for both box1 and box2 motifs in JAK interaction and activation 10, 11, 17 . The box1 and box2 motifs in human gp130 and EPO-R are separated by 32 and 43 residues, respectively, thus suggesting the possibility of multiple peptide-interaction sites in the JAK FERM and SH2 domains 2 . Yet what is clear from this work and the work of others 13 is that IFNAR1 does not require a classical proline-rich box1 sequence to interact with TYK2. This raises the question of whether IFNAR1 has lost its box1 motif or instead is a 'minimal' receptor motif emblematic of JAKreceptor interactions. Intriguingly, our alignment of receptor intracellular domains on the basis of their box2 motifs (Fig. 5b) reveals that IFNAR2 contains a box1 sequence (Pro-Phe-Pro), shown to be required for JAK1 interaction 15 , ten residues upstream of box2. This places the IFNAR2 box1 in near-exact alignment with the dileucine motif in IFNAR1 and leads us to speculate that the segment 1 dileucine interaction site in TYK2 may be the JAK box1 interaction site. IL13Ra1  IL12Rb1  IL10R2  gp130  IFNAR2  IL10R1  IL2Rb  IL4Ra  IL12Rb2  IFNGR1  Beta  IFNGR2 EPO-R HGHR GMCSFR IL3R IL5R Gamma npg Overall, our structural work has begun to unravel the 'code' by which JAKs interact with their receptors and indicates that receptors follow a multipoint JAK-interaction blueprint, using the conserved SH2-box2 interaction typified by TYK2 and IFNAR1, as well as interactions with box1 or other surrounding motifs, to secure a tight interface between JAK and receptor. This structural arrangement appears uniquely suited to allow high fidelity and specificity in the constitutive coupling of a broad family of cytokine receptors with their downstream signaling amplifiers.
METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes.
Coordinates and structure factors have been deposited in the Protein Data Bank under accession code 4PO6.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
ONLINE METHODS
Protein expression and purification for crystallization. The human TYK2 FERM-SH2 domain (amino acids 23-583) linked by a 6× Gly-Ser (GSGSGSGSGSGS) linker to a fragment of the human IFN-α receptor chain 1 (IFNAR1, amino acids 478-512) was cloned into the bacterial expression vector pET32a in frame with the N-terminal thioredoxin tag and a TEV protease cleavage site. The construct was transformed into Rosetta 2 (DE3) Escherichia coli competent cells for expression. Single-colony overnight starter cultures grown in TB with 1% glycerol were used for inoculation of production cultures in Instant TB overnight autoinduction medium (Novagen) and grown at 16 °C for 4 d. For selenomethionine labeling, the above construct was transformed into BL21 (DE3) Gold E. coli competent cells. Single-colony overnight starter cultures grown in minimal medium (M9 medium with 0.4% glucose, 0.1% ammonium chloride, 2 mM magnesium sulfate, 0.1 mM calcium chloride, trace metals, and vitamin mix) were used for inoculation of production cultures in minimal medium and grown at 37 °C to an OD of 0.6. Cultures were shifted to 16 °C, supplemented with 100 mg/L l-lysine, l-phenylalanine, l-threonine and 50 mg/L l-isoleucine, l-leucine, l-valine and l-selenomethionine for 30 min and induced with 0.4 mM IPTG overnight.
After expression, cells were harvested by centrifugation, and bacterial paste was resuspended in buffer containing 50 mM Tris, pH 8.0, 500 mM NaCl, 10% glycerol, 5 mM imidazole, 1 mM TCEP, 0.1 mM PMSF and EDTA-free PI tablets (Roche). Cells were lysed by homogenization and microfluidization, and lysate was incubated with 0.25% CHAPS for 1 h at 4 °C before ultracentrifugation at 40,000 r.p.m. for 45 min. Cleared lysate was filtered with an 0.8-µM filter before being loaded onto a Ni-NTA Superflow gravity (Qiagen) column. The Ni-NTA column was washed with lysis buffer supplemented with 0.1% CHAPS and 40 mM imidazole, and TYK2 protein was eluted in lysis buffer supplemented with 0.1% CHAPS and 300 mM imidazole. The TYK2 elution pool was concentrated and loaded onto a 
Protein expression and purification for SEC analysis and mass spectrometry.
For baculovirus expression, the human TYK2 FERM-SH2 domain (amino acids 23-566) linked by a 2× Gly-Ser-TEV-2× Ser-Gly (GSGSENLYFQGSGSG) linker to a fragment of the IFN-α receptor chain 1 (IFNAR1, amino acids 465-512) was cloned into the baculovirus expression vector pAcGP67 in frame with an N-terminal His 6 tag and TEV cleavage site (MHHHHHHGENLYFQGS). For expression without the IFNAR1 peptide, TYK2 (amino acids 23-566) was cloned into the same pACGP67 N-His-TEV vector. SF9 cells were infected with resulting virus at an MOI of 1.0, grown in shaker cultures for 72 h at 27 °C and harvested by centrifugation. Cell pellets were resuspended in buffer containing 50 mM Tris, pH 8.5, 500 mM NaCl, 10% glycerol, 5 mM imidazole, 1 mM TCEP, 0.25 mM PMSF, and EDTA-free PI tablets (Roche) and lysed by homogenization and microfluidization. Lysate was incubated with 0.25% CHAPS for 1 h at 4 °C before ultracentrifugation at 40,000 r.p.m. for 45 min. Cleared lysate was filtered with an 0.8-µM filter before being loaded onto a Ni-NTA Superflow gravity column. The Ni-NTA column was washed with lysis buffer supplemented with 0.1% CHAPS and 40 mM imidazole, and TYK2 protein was eluted in lysis buffer supplemented with 0.1% CHAPS and 300 mM imidazole. The TYK2 elution pool was concentrated and loaded onto a HiLoad 16/60 Superdex 200 prep-grade column (GE Healthcare) in 20 mM Tris, pH 8.8, 300 mM NaCl, 10% glycerol and 1 mM TCEP.
Mass spectrometry. MS was performed on an Agilent 6224 TOF LC/MS system coupled to an Infinity 1260 HPLC. Proteins were separated on a PLRP-S reversed-phase column with a water-acetonitrile gradient with 0.05% trifluoroacetic acid as a counterion. MS data were analyzed with MassHunter (Agilent).
Differential scanning fluorimetry (DSF). To generate IFNAR1 receptor mutants for DSF, the E. coli expression construct described above (pET32A containing TYK2 FERM-SH2 residues 23-583, 6× Gly-Ser linker and IFNAR1 residues 478-512) was subjected to site-directed mutagenesis to generate the L491A L492A, E496A, E497A, E496A E497A and E500A mutants. All constructs were transformed into Rosetta 2 (DE3) E. coli grown in autoinduction medium and purified as described for crystallography. An 0.8-µM protein sample was prepared in a 1:2,000 dilution of SYPRO orange dye/protein buffer (25 mM Tris, 250 mM NaCl, and 1 mM TCEP, pH 7.5). An AB7500 qPCR machine was used to heat the sample from 25 °C to 95 °C, and fluorescence measurements were taken at 1 °C increments. Thermal melting curves were plotted, and the ThermoFluor analyzer software was used to generate apparent T m values according to published methods 42, 43 . Mean apparent T m , s.d., and P values were calculated from measurements of more than six individual wells for each protein. Apparent T m values for wild-type TYK2-IFNAR1 were measured as a control in three separate experiments on different days, and these 25 data points were used to calculate the mean wild-type T m as well as subjected to an unpaired, two-tailed t test against the mutant-receptor data points to determine P values. Sample sizes for mutants were as follows: L491A L492A, 9; E496A, 12; E497A, 21; E496A E497A, 12; E500A, 6. Individual traces are shown in Supplementary Figure 5 . We were unable to calculate apparent T m values for the TYK2 FERM-SH2 without peptide because of poor recovery of soluble protein after the SEC step (Supplementary Fig. 1) .
Histidine-and GST-pulldown experiments. pACGP67-based baculovirus expression constructs were generated for N-His 6 -TEV-tagged human TYK2 FERM-SH2 (residues 23-566) and N-GST-tagged IFNAR1 (residues 465-512). GST-IFNAR1 variants (E496A, E497A, and E496A E497A) were generated by site-directed mutagenesis. For protein expression, SF9 cells were infected with virus at an MOI of 1.0, grown in shaker cultures for 72 h at 27 °C and harvested by centrifugation. Cell pellets from 1 l of SF9 culture were resuspended in 120 mL buffer containing 50 mM Tris, pH 8.5, 300 mM NaCl, 10% glycerol, 1 mM TCEP, 0.25 mM PMSF and EDTA-free PI tablets (Roche) and were lysed by homogenization and microfluidization. Lysates were incubated with 0.25% CHAPS for 1 h at 4 °C before ultracentrifugation at 40,000 r.p.m. for 45 min. Cleared lysates were filtered with an 0.8-µM filter and divided in half for Ni-or glutathione-affinity purification. For Ni-NTA purification, 50 mL of lysate was loaded onto a 3-mL Ni-NTA Superflow (Qiagen) gravity column, and the column was washed with ten column volumes of lysis buffer supplemented with 0.1% CHAPS and 40 mM imidazole. Bound proteins were eluted in one column volume of lysis buffer supplemented with 0.1% CHAPS and 300 mM imidazole. For GST purification, 50 mL of lysate was bound to 2.5 mL Glutathione-Sepharose FF resin (GE Healthcare) in batch for 2 h at 4 °C, and this was followed by on-column washing with ten column volumes of lysis buffer supplemented with 0.1% CHAPS. Bound proteins were eluted in one column volume of lysis buffer supplemented with 0.1% CHAPS and 10 mM reduced glutathione. Eluates were analyzed by SDS-PAGE and visualized with a Bio-Rad stain-free scanning system (GelDoc EZ System).
Crystallization and data collection. TYK2-IFNAR1 crystals were initially grown in hanging drops at 4 °C by mixture of 1 µL of concentrated protein with 1 µL of mother liquor consisting of 0.1 M Tris HCl, pH 7.0, 0.2 M MgCl 2 , and 8-12% PEG 8000. Optimization of both native and selenomethioninederivatized crystals was carried out by microseeding and varying the protein/ mother liquor ratio. Heavy-atom derivatives were prepared by soaking the crystals for 1 h in 0.1 M Tris HCl, pH 7.0, 0.2 M MgCl 2 and 12% PEG 8000 supplemented with 5% glycerol and 1 mM of KAu(CN) 2 or K 2 PtCl 4 . All crystals were back-soaked and cryoprotected by stepped introduction of mother liquor containing glycerol (5%:15%:25% v/v) into the drop, and this was followed by flash freezing in liquid nitrogen. The native data set (0.979 Å) was collected at the Stanford Synchrotron Radiation Lightsource (SSRL) beamline 12-2, and peak wavelength selenomethionine-(0.9789 Å), gold-(1.0378 Å) and platinumderivative (1.0716 Å) data sets were collected at SSRL beamline 11-1. All data were collected under cryocooled conditions (100 K) and processed with XDS 44 and SCALA 45 . The native TYK2-IFNAR1 crystal data belonged to the C2 space group, with unit-cell parameters of a = 186.4 Å, b = 52.4 Å, c = 70.2 Å, α = 90, β = 108, and λ = 90. Derivatized TYK2-IFNAR1 crystals also belonged to the C2 space group, with unique a-axis lengths and β angles ( Table 1) .
Phasing and structure determination. Phases were calculated by the singlewavelength anomalous dispersion (SAD) method with Autosol from the Phenix package 46 . The calculated phases for the gold and platinum data sets had figureof-merit values of 0.406 and 0.322, respectively. An initial model containing polyalanine helices and strands was built from the heavy atom-phased maps by Phenix Autobuild. Because the anomalous signal in the selenomethionine data set was too weak to provide phases, the polyalanine model was used as a molecular-replacement model to calculate phases for the selenomethionine data. An anomalous difference map generated with FFT in the CCP4 suite 45 and contoured to 4σ provided the positions of seven of ten methionines (100, 115, 141, 186, 256, 445, and 564) in the polypeptide. This information, combined with the location of several gold and platinum sites (assumed to be bound to cysteines and methionines, respectively), provided the initial register for manual addition of side chains to the polyalanine model. Several rounds of model building in COOT 47 and simulated annealing refinement in Phenix provided a coordinate set suitable for molecular replacement into the high-resolution native data. This was followed by another round of automated chain building with Phenix Autobuild. This method provided a model that was approximately 80% complete. Final rounds of model building and addition of water and solvent molecules was carried out with COOT. This was followed by simulated annealing, coordinate and B-factor refinement with Phenix and BUSTER (http://www.globalphasing. com/buster/). The final model was refined at 2.0 Å to R/R free values of 19.9/23.3% respectively, and Ramachandran statistics calculated by MolProbity 48 indicated that 98% of residues lie in the favored regions, with 0.2% outliers. The final model contains TYK2 residues 26-129, 139-295, 309-329, 371-509, and 513-566 and IFNAR1 residues 489-507. Contacts were analyzed with the Protein Interfaces, Surfaces and Assemblies (PISA) software 49 and CONTACT from the CCP4 suite 45 . Structural superpositions were carried out with the SSM algorithm from SUPERPOSE 45 . Structural figures were prepared with PyMOL (http://www. pymol.org/). Surface electrostatics were calculated with APBS 50 .
Sequence alignments and analysis. FERM-SH2 sequence conservation analysis shown in Figure 5 was generated by CONSURF 51 with the TYK2 FERM-SH2 structure as a model and a PSI-BLAST search against the Uniref90 database over the FERM-SH2 amino acid sequence, with cutoffs set at a maximum 95% and a minimum of 35% identity. 143 JAK family sequences were used in the analysis and are listed in Supplementary Table 1 . Other sequence alignments were generated with PROBCONS 52 . Owing to poor sequence homology among receptors, sequence alignments shown in Figure 5 were aligned by hand on the basis of both published and predicted box2 sequences from human receptors.
